



Good food, Good life

Press Release

Ad hoc announcement pursuant to Art. 53 LR

Vevey, September 4, 2023

[FR](#) | [DE](#)

Full details on our [website](#)

Nestlé divests its *Palforzia* business

Nestlé announced today that it has divested *Palforzia*, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company which specializes in the diagnosis and treatment of allergies. The transaction was closed upon signing.

This agreement follows Nestlé's announcement last year that it would conduct a strategic review of *Palforzia*. Nestlé will receive milestone payments and ongoing royalties from Stallergenes Greer.

"We are confident that Stallergenes Greer will take *Palforzia* forward and ensure this unique treatment supports patients around the world," said Greg Behar, CEO of Nestlé Health Science. "At the same time, the divestiture allows Nestlé Health Science to focus on its core strengths and key growth drivers. "

There will be a customary transition period to ensure business continuity and give patients uninterrupted access to the treatment.

Contacts:

Media	Christoph Meier	Tel.: +41 21 924 2200	mediarelations@nestle.com
Investors	Luca Borlini	Tel.: +41 21 924 3509	ir@nestle.com